reiterateTXGfinnhub
Stephens & Co. Reiterates Overweight Rating on 10x Genomics, Inc. (TXG)
Stephens & Co. reiterated its Overweight rating on 10x Genomics, Inc.
Read moreFeatured By
Real-time context
Upgrades, downgrades, initiations, and price-target changes.
Stephens & Co. reiterated its Overweight rating on 10x Genomics, Inc.
Read moreMorgan Stanley reiterated its Equal-Weight rating on PENN Entertainment, Inc. (NASDAQ:PENN) on August 12, 2026.
Read moreBarclays reiterated its Overweight rating on Legend Biotech Corporation (NASDAQ:LEGN) on August 12, 2026.
Read moreRBC Capital reiterated its Outperform rating on Legend Biotech Corporation (NASDAQ:LEGN) on August 12, 2026.
Read moreMorgan Stanley reiterated its Overweight rating on Legend Biotech Corporation (NASDAQ:LEGN) on August 12, 2026.
Read moreTD Cowen reiterated its Hold rating on Legend Biotech Corporation (NASDAQ:LEGN) on August 12, 2026.
Read moreOppenheimer analysts downgraded Legend Biotech Corporation (NASDAQ:LEGN) from Outperform to Perform on August 12, 2026.
Read moreHC Wainwright & Co. reiterated its Buy rating on Vera Therapeutics, Inc.
Read moreCantor Fitzgerald reiterated its Overweight rating on Firefly Aerospace Inc. Common Stock (NASDAQ:FLY) on August 12, 2026.
Read moreRoth Capital reiterated its Buy rating on Firefly Aerospace Inc. Common Stock (NASDAQ:FLY) on August 12, 2026.
Read moreB. Riley Securities reiterated its Buy rating on Firefly Aerospace Inc.
Read moreOppenheimer reiterated its Outperform rating on CarGurus, Inc. (NASDAQ:CARG) on August 12, 2026.
Read moreBTIG analysts downgraded Apogee Therapeutics, Inc. (NASDAQ:APGE) from Buy to Neutral on August 12, 2026.
Read moreBarclays reiterated its Overweight rating on Transocean Ltd. (NYSE:RIG) on August 12, 2026.
Read moreTD Cowen reiterated its Buy rating on CAVA Group, Inc. (NYSE:CAVA) on August 12, 2026.
Read moreRBC Capital reiterated its Outperform rating on CAVA Group, Inc. (NYSE:CAVA) on August 12, 2026.
Read moreMizuho reiterated its Neutral rating on CAVA Group, Inc. (NYSE:CAVA) on August 12, 2026.
Read moreKeybanc reiterated its Overweight rating on CAVA Group, Inc. (NYSE:CAVA) on August 12, 2026.
Read moreRoth Capital reiterated its Buy rating on CAVA Group, Inc. (NYSE:CAVA) on August 12, 2026.
Read moreWolfe Research reiterated its Outperform rating on CAVA Group, Inc. (NYSE:CAVA) on August 12, 2026.
Read more